Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nrrheum.2016.136 http://scihub22266oqcxt.onion/10.1038/nrrheum.2016.136 C5500215!5500215!27539668     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Rev+Rheumatol 2016 ; 12 (10): 580-92 Nephropedia Template TP {{tp|p=27539668|t=2016. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis |pdf=|usr=}}{{27539668}} gab.com Text Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis JO: Nat Rev Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27539668 #FOAvip Osteoarthritis (OA) has long been viewed as a degenerative disease of cartilage, but accumulating evidence indicates that inflammation has a critical role in its pathogenesis. Furthermore, we now appreciate that OA pathogenesis involves not only breakdown of cartilage, but also remodelling of the underlying bone, formation of ectopic bone, hypertrophy of the joint capsule, and inflammation of the synovial lining. That is, OA is a disorder of the joint as a whole, with inflammation driving many pathologic changes. The inflammation in OA is distinct from that in rheumatoid arthritis and other autoimmune diseases: it is chronic, comparatively low-grade, and mediated primarily by the innate immune system. Current treatments for OA only control the symptoms, and none has been FDA-approved for the prevention or slowing of disease progression. However, increasing insight into the inflammatory underpinnings of OA holds promise for the development of new, disease-modifying therapies. Indeed, several anti-inflammatory therapies have shown promise in animal models of OA. Further work is needed to identify effective inhibitors of the low-grade inflammation in OA, and to determine whether therapies that target this inflammation can prevent or slow the development and progression of the disease. Twit Text FOAVip Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis ????Nat Rev Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27539668 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27539668 #FOAvip English Wikipedia <ref>{{Cite pmid|27539668}}</ref> Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis #MMPMID27539668 Robinson WH; Lepus CM; Wang Q; Raghu H; Mao R; Lindstrom TM; Sokolove J Nat Rev Rheumatol 2016[Oct]; 12 (10): 580-92 PMID27539668show ga Osteoarthritis (OA) has long been viewed as a degenerative disease of cartilage, but accumulating evidence indicates that inflammation has a critical role in its pathogenesis. Furthermore, we now appreciate that OA pathogenesis involves not only breakdown of cartilage, but also remodelling of the underlying bone, formation of ectopic bone, hypertrophy of the joint capsule, and inflammation of the synovial lining. That is, OA is a disorder of the joint as a whole, with inflammation driving many pathologic changes. The inflammation in OA is distinct from that in rheumatoid arthritis and other autoimmune diseases: it is chronic, comparatively low-grade, and mediated primarily by the innate immune system. Current treatments for OA only control the symptoms, and none has been FDA-approved for the prevention or slowing of disease progression. However, increasing insight into the inflammatory underpinnings of OA holds promise for the development of new, disease-modifying therapies. Indeed, several anti-inflammatory therapies have shown promise in animal models of OA. Further work is needed to identify effective inhibitors of the low-grade inflammation in OA, and to determine whether therapies that target this inflammation can prevent or slow the development and progression of the disease. äLow-grade inflammation as a key mediator of the pathogenesis of osteoa(epmc).pdf DeepDyve Pubget Overpricing